Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QY-1-T in HBV-associated Advanced Liver Cancer
NCT06251115Phase 1Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QY-1-T in hepatocellular carcinoma (HCC), sponsored by Shanghai General Hospital. Primary endpoint: Dose Limiting Toxicities at 1 month. Started Jan 2024; status: recruiting.
02
Drugs
QY-1-T
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06251115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251115.